Ligand Pharmaceuticals Inc

25 Aug 2026, 19:46 UTC

Ligand Pharmaceuticals Inc is trading higher, benefiting from a favorable market environment amid declining crude oil prices and lower Treasury yields.

24 Aug 2026, 19:56 UTC

Ligand Pharmaceuticals is trading lower during Monday's session, marking the fourth consecutive day of declines. No specific news has been identified to explain the drop.

21 Aug 2026, 19:36 UTC

Ligand Pharmaceuticals is gaining today, supported by strong long-term performance and a market capitalization of $5.76 billion.

19 Aug 2026, 19:11 UTC

Ligand Pharmaceuticals Inc is rising today, driven by strong momentum in the Pharmaceuticals sub-sector and unusually high market volume.

18 Aug 2026, 19:16 UTC

Ligand Pharmaceuticals Inc is trading lower, continuing a downward trend amid rising U.S. Treasury yields and inflation concerns related to geopolitical tensions.

17 Aug 2026, 20:06 UTC

Ligand Pharmaceuticals Inc is declining during Monday's session, amid broader economic concerns following a drop in U.S. retail sales for July.

14 Aug 2026, 19:46 UTC

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

13 Aug 2026, 19:52 UTC

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12 Aug 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11 Aug 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10 Aug 2026, 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7 Aug 2026, 20:02 UTC

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6 Aug 2026, 20:03 UTC

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5 Aug 2026, 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3 Aug 2026, 19:36 UTC

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31 Jul 2026, 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30 Jul 2026, 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29 Jul 2026, 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28 Jul 2026, 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27 Jul 2026, 19:26 UTC

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24 Jul 2026, 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23 Jul 2026, 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21 Jul 2026, 20:02 UTC

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.